While the benefit of risk-reducing surgeries in preventing second cancers in women with DCIS and PV in BRCA1 or BRCA2 are well established, preventing recurrence without overtreatment for women with PV in other genes is more challenging. The gene discussed is BRCA2; the disease is ductal breast carcinoma in situ.